|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Eligible patients were anti-TNF naïve adults with moderately to severely active UC.
|
29372480 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach.
|
29205406 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Adalimumab is a recombinant monoclonal antibody to tumor necrosis factor alpha (TNFα) used in the treatment of inflammatory and autoimmune conditions, including ulcerative colitis (UC).
|
30648028 |
2018 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Combination therapy was not superior in any of the registration trials for Crohn's disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab.
|
29462391 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cumulative incidence of anti-TNF exposure varied from 20.9% to 31.4% for CD and from 8.0% to 13.5% for UC.
|
30205699 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The risk of death was statistically significantly lower in patients treated with anti-TNF therapy for CD (21.4 vs. 30.1 per 1,000 person-years, OR 0.78, 0.65-0.93) but not for UC (23.0 vs. 30.9 per 1,000 person-years, OR 0.87, 0.63-1.22).
|
29336432 |
2018 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) refractory or intolerant to either conventional therapy or TNFα inhibitors.
|
29930467 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
CD was more commonly treated with anti-TNF than UC (40% vs. 10%, p<0.001).
|
30009157 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared with the model group, the general relative indices results showed L. plantarum ZDY2013 and B. bifidum WBIN03 have a significant effect on DSS-induced UC in mice, by downregulating the pro-inflammatory cytokines (e.g., TNF-α) and upregulating antioxidant factors (e.g., SOD1, SOD2, GPX2) at the transcriptional level.
|
29401402 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Randomized controlled trials (RCTs) have demonstrated that therapies targeting tumor necrosis factor (TNF) and α₄β₇ integrin are effective when given as monotherapy in inducing and/or maintaining remission in patients with ulcerative colitis (UC) or Crohn's disease (CD), but data from RCTs are less clear on whether concomitant immunomodulator (IM) therapy confers additional benefit.
|
29505910 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ninety five adults with steroid-dependent active UC and insufficient response/intolerance to IS and/or TNF inhibitors received 5-8 aphereses in a single induction series of ≤10 weeks.
|
29513111 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
COX-2-PGE<sub>2</sub> Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis.
|
30190207 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CX-10 treatment attenuated DSS-induced UC in mice through inhibiting the activation of NF-κB and MAPK pathways and reducing TNF-α and IL-6 levels, suggesting that CX-10 is a potential therapeutic drug for UC.
|
29475099 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured.
|
29333082 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Results show that the UC group had higher expression levels of TNF-α, IL-6, IFN-γ, MPO, MDA, NO, STAT3 and JAK and lower expression levels of IL-10, SOD, miR-495 and Claudin-1, compared to the normal group.
|
29129493 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we show that levels of peripheral blood cytokines IL-9, IL-8, IL-10, IL-6, IL-1β, IL-12, and tumor necrosis factor (TNF) were higher in patients with UC than normal control, and serum and local IL-9 levels were positively correlated with the disease activity grade.
|
30369485 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis.
|
29361101 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Also HASG was found to reduce the levels of TNF-α and IL-6, thereby suppressing their inflammatory response in UC.
|
29530609 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TNFα was upregulated in intestinal biopsies from active Crohn`s disease [CD] vs controls [36.2 vs 12.1, p < 0.001], but not ulcerative colitis [UC: 17.9].
|
29182760 |
2018 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis.
|
30315858 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Circulating monocytes from active ulcerative colitis (UC) patients produced high levels of tumor necrosis factor-alpha(TNFα) and interleukin(IL)-6 after Toll-like receptors (TLR) stimulation.
|
29529212 |
2018 |
|
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As combination therapy is an emerging strategy for UC treatment, we attempt to treat established UC based on the combination of TNFα siRNA (siTNF) and IL-22.
|
30107214 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, bioptic samples from UC patients incubated with LGG conditioned media (CM) showed reduced expression of TNFα and IL-17 compared with the corresponding expression in controls (<i>P</i> < 0.05).
|
30416313 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both CD and UC samples exhibited gene and protein expression of HLA-G; and the HLA-G5 expression is differentially correlated with TNF and IL-10 levels depending on the type of the underlying inflammatory bowel disorder.
|
29588183 |
2018 |
|
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In ulcerative colitis (UC) patients, cytapheresis depletes elevated and activated leucocytes, which are known to release inflammatory cytokines including tumor necrosis factor (TNF)-α.
|
28581039 |
2018 |